Junctional adhesion molecule-like protein (JAML) (JAML)

Junctional adhesion molecule-like protein (JAML), also known as AMICA1, is a transmembrane protein belonging to the immunoglobulin superfamily that plays a pivotal role in the JAML/SIRT1 signaling axis within the kidney [1, 2]. In diabetic kidney disease (DKD), JAML expression is significantly upregulated in podocytes, leading to the suppression of Sirtuin 1 (SIRT1) activity [2]. This downregulation of SIRT1 results in the loss of essential podocyte proteins, such as nephrin and podocin, which are critical for maintaining the glomerular filtration barrier [2, 3]. The activation of JAML signaling promotes podocyte injury, inflammation, and the progression of albuminuria [2]. Consequently, JAML is considered a potential therapeutic target, where its inhibition could restore SIRT1-mediated protective pathways and preserve renal function [2]. While specific JAML inhibitors are currently in the experimental stage, targeting this axis offers a novel approach to treating diabetic nephropathy and other proteinuric diseases [2, 3].

Other names

AMICA1Adhesion molecule interacting with CXADR antigen 1AMICACREA7-1Gm638

JAML inhibition prevents the downregulation of SIRT1, thereby maintaining the acetylation status of target proteins and preserving podocyte structural integrity [2].